Is Nilotinib safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Nilotinib. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
A woman with chronic myeloid leukemia received nilotinib (dosage not stated) for 20 months before pregnancy, throughout pregnancy and continuing during 9 months of breastfeeding (extent not stated). No adverse reactions were reported in her breastfed infant.[ 4 ]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. One woman with Ph+ chronic myelocytic leukemia was taking nilotinib before pregnancy, but stopped until breastfeeding ceased. She received one dose of nilotinib 400 mg orally and took milk samples at 1, 2, 4, 6, 8, 12 and 24 hours after the dose. She had a peak milk concentration of 129 mcg/L at 4 hours after the dose.[ 2 ] These data were incorporated into a physiologically based pharmacokinetic model that predicted the pharmacokinetic profile relatively well. However, more data are needed to validate the model.[ 3 ] Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.